Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Hadasit, the technology transfer company of the Hadassah Medical Organization, and Immuron, a biopharmaceutical company, have signed an agreement whereby Immuron will assign from Hadasit a novel oral immune modulation technology that was developed by Hadassah physicians and scientists.
Subscribe to our email newsletter
The combination of Hadasit’s oral immune modulation with Immuron’s existing oral protein and antibody technology could yield a convenient, all-natural, side-effect-free approach to address serious diseases including metabolic syndrome, hepatitis C and type 2 diabetes.
Under the terms of the agreement, Hadasit will also provide clinical and laboratory services to Immuron, providing Immuron with efficiencies in its cost structure for human clinical trials. In return, Hadasit shall be issued 19.99% of Immuron’s equity at the time of the approval of the transaction by Immuron’s shareholders, as well as royalties on Immuron products.
In addition, Yaron Ilan from Hadassah Medical Center will become the chief medical officer of Immuron. Dr Ilan will continue to serve simultaneously as the director of the department of medicine A at the Hadassah Ein-Kerem University Hospital, and the deputy dean of the Hebrew University Hadassah School of Medicine in Jerusalem.
Immuron will focus its initial clinical development effort with this combination platform technology on three major diseases: metabolic syndrome, chronic hepatitis C (HCV) and liver cancer.
Immuron intends to first initiate clinical trials for metabolic syndrome and HCV shortly after the acquisition. Given that the products are intended to be marketed as a medical food in the US, it is expected that Immuron can introduce commercial products for some indications shortly after the successful conclusion of these trials, potentially within two-three years.
The new platform technology will also provide an additional layer of patent protection to strengthen the existing Immuron pipeline products, which target traveller’s diarrhea, HIV/AIDS immune depletion, mucositis and influenza.